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SUMMARY – Extracorporeal shockwave lithotripsy is not a novel therapeutic method in the 
treatment of urolithiasis. It uses shock waves (SW) created in the generator outside of the body that 
are then focused and directed on the calculus in the patient’s body. It is the method of choice for the 
treatment of kidney stones smaller than 20 mm, and those in the proximal part of the ureter (up to 10 
mm). Complications are relatively rare and most often clinically insignificant. SW can reversibly 
 damage all parts of the renal parenchyma. The degree of damage depends on the number of SW and 
the energy level delivered to a particular tissue. Such changes are most often asymptomatic. Microhae-
maturia is present in virtually all patients, and macrohaematuria occurs in about 1/3 of patients. A rare 
but serious complication is a kidney rupture that requires surgical care that can sometimes lead to a 
nephrectomy. The occurrence of perinephric or subcapsular hematoma is rare and usually requires only 
conservative therapy. Despite the aforementioned negative impact of SW on the renal parenchyma 
(primarily around the calculus), studies have not shown that treatment with this method leads to 
significant renal function impairment in either the adult or paediatric population.
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Introduction
Urolithiasis is a significant health problem as its in-
cidence is from 1 to 20% in adults and from 0.1 to 5.5% 
in children1,2. Over the last few decades, the incidence of 
urinary stones has increased worldwide for all sex, age, 
and race groups. This has been linked to dietary changes, 
obesity, and also climate change. According to steadily 
increasing incidence, we can expect it to be a climate-
related disease by the end of the century3.
Extracorporeal shockwave lithotripsy (ESWL) is a 
non-invasive, relatively safe, and highly effective treat-
ment for urinary stones in appropriately selected pa-
tients, thus making it a very attractive method. It em-
ploys high energy acoustic waves (shock waves) out-
side the body to target and break stones within the 
kidney and the ureter. The mechanism behind break-
age is direct stress induced by the compressive positive 
pressure phase of the shock wave (SW) and cavitation, 
formation of the bubbles that erode the stone surface 
during the negative pressure phase4. ESWL can also 
be used in gastroenterology and orthopaedics.
Indication and contraindications for ESWL
ESWL is indicated for patients with symptomatic, 
uncomplicated kidney stones up to 20 mm in diameter 
and for stones of proximal ureter up to 10 mm. Larger 
kidney stones can be treated, but it is advised to insert 
a ureteral stent prior to the procedure to prevent ob-
struction with stone fragments and „stein strasse“ for-
mation. Elimination of fragments is aggravated for 
stones located in the lower calyx, so the recommended 
diameter should not exceed 15 mm. Also, some types 
of stones do not respond well to ESWL, such as cal-
cium oxalate monohydrate stones, brushite stones, and 
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a sub-type of cystine stones. In some cases, repeated 
treatments may be needed.
There are few absolute contraindications for ESWL 
and it should never be conducted in pregnant women 
and patients with an uncorrected coagulation disorder. 
Patients who have anatomical abnormalities of the 
urinary tract that could hinder fragment passage, such 
as ureteropelvic junction obstruction or ureteral stric-
ture, should be excluded. Severe untreated hyperten-
sion is an excluding factor until the blood pressure is 
controlled, as it poses a greater risk of developing renal 
haemorrhage during the procedure. Active urinary 
tract infection is also a contraindication due to the risk 
of pyelonephritis or sepsis. Prior to the procedure, all 
patients should do a urine sampling for bacteriuria and 
pyuria, and in case of positive results, a urine culture 
and antibiotic treatment should be done5. Staghorn 
stones and large stones with a diameter over 20 mm 
are a relative contraindication. Also, aortic aneurysms 
and renal artery aneurysms are relative contraindica-
tions as they can result in life-threatening haemor-
rhage. Patients with skeletal deformities are not con-
traindicated, though it may be impossible to carry out 
ESWL. If the favourable SW path can be established, 
patients with skeletal deformities should not be ex-
cluded6.
In some patient groups, extra precautions should be 
taken during the procedure because of a greater risk of 
complications: patients with hypertension, diabetes 
mellitus, cardiovascular disease, reduced renal func-
tion, solitary kidney, in children and elderly patients. It 
is advised to closely monitor blood pressure and ECG 
during the treatment.
Complications of the procedure
Almost all patients who undergo ESWL experi-
ence microhaematuria and macrohematuria occurs in 
about 1/3 of patients. Macrohaematuria is rarely se-
vere, so in most cases does not require further medical 
interventions.
Incomplete stone fragmentation can lead to uri-
nary tract obstruction if the fragments remain larger 
than 5 mm. Incomplete fragmentation is more com-
mon with stones of larger surface and harder composi-
tion (e.g. brushite stones). Obstruction of the upper 
urinary tract can cause flank pain and colic, hydrone-
phrosis, acute kidney damage, alteration in glomerular 
filtration rate (GFR), and urinary tract infections. 
Placement of the internal stent or percutaneous neph-
rostomy may be needed to bypass the obstruction, de-
pending on the stone size, kidney function parameters, 
Fig. 1. CT scan of the large subcapsular renal hematoma after ESWL (1 day after treatment) performed for treatment 
of stone in the right kidney (A-frontal view, B-transverse view). With conservative therapy, three months after ESWL 
treatment, complete resolution of the hematoma was achieved.
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and patient’s general state. If the obstruction does not 
resolve spontaneously, further ESWL or endoscopic 
procedures may be needed.
Damage to the renal tissue can affect all parenchy-
mal components. The degree of damage is reciprocal to 
the level of energy and the number of SW delivered. 
Blood vessels are most commonly damaged, and as a 
result, subcapsular of perinephric haemorrhage with 
ipsilateral pain can happen, but irreversible acute renal 
failure was also described, most likely due to injury of 
glomerular corpuscles6. Subcapsular hematoma is a 
consequence of a ruptured large vessel in the renal cap-
sule (Fig. 1). The incidence of hematomas ranges from 
1% to 20%, depending on the variety of the lithotripter 
used for the procedure, radiological imaging method, 
and time of the assessment. The most important risk 
factor for developing hematomas is age, as incidence 
increases by double per decade, with untreated or un-
corrected hypertension, diabetes mellitus, and general-
ized vascular calcification. Most hematomas resolve 
without any medical implication within weeks or 
months, without any long-term effects on the renal 
function, although, in some severe cases, they may re-
sult in lethal outcome4,7.
Extrarenal damage to the other organs that has 
been described includes perforation of the colon, he-
patic hematoma, rupture of the hepatic artery, acute 
necrotizing pancreatitis, rupture of the spleen, rupture 
of the abdominal aorta, dissecting abdominal wall ab-
scess, iliac vein thrombosis, pneumothorax, urinotho-
rax, among others.
Short-term effects on kidney function
Kidney injury is inevitable during every ESWL 
treatment and this process continues even when the 
procedure is finished. Effects of shock waves on kidney 
tissue can be distinguished into two major types: isch-
emic and traumatic vascular injury, and both of them 
have a different pathophysiological basis8-10. Traumatic 
injury is provoked by the sheer shock waves physical 
force. The ischemic (hypoxic) injury appears in both 
kidneys, not just the treated one, and is caused by renal 
vasoconstriction together with intraparenchymal 
bleeding. Oxidative stress mediated by ischemia-re-
perfusion might impart to kidney injury. In the last 
couple of years, a significant effort has been invested 
into finding specific biomarkers sensitive enough to 
detect subclinical acute kidney injury, independently 
of GFR and diuresis. A number of biomarkers have 
been investigated: β2-microglobulin, TNF-α, interleu-
kins, N-acetyl-beta-D-glucosaminidase (NAG), urine 
neutrophil gelatinase-associated lipocalin (uNGAL), 
cystatin C and some others8-19.
Urinary β2-microglobulin is a low molecular mass 
protein that is reabsorbed nearly by 100% in proximal 
tubules and therefore is a sensitive marker of proximal 
tubule cell damage11,12. The increase of β2-microglobu- 
lin in urine after ESWL results from tubular cell dam-
age that reduces reabsorption capacity due to isch-
emic-reperfusion injury and oxidative stress10,13. 
Nasseh et al. proved in a cross-sectional study on 91 
patients with nephrolithiasis who underwent ESWL 
(power level 3, 2500 SW) that the urinary excretion of 
β2-microglobulin increased by 167% immediately af-
ter treatment14. Li et al. performed a study on an ani-
mal model of rats that showed that β2-microglobulin 
and IL-18 levels in urine stay significantly elevated 
even at 105 days post ESWL, as a consequence of in-
flammatory response to treatment15.
Interleukins take part in regulating immune re-
sponse and inflammatory reactions, and interleukin-1 
(IL-1) and interleukin-6 (IL-6) have been linked with 
post-ESWL renal injury16. Goktas et al. assessed the 
severity of the inflammatory response to ESWL in 35 
patients by measuring the urinary excretion of IL-1 
and IL-6. In the early post ESWL period, they ob-
served a rise in IL-6 excretion compared to the control 
group, but after 14 days, the concentration decreased 
rapidly. On the contrary, IL-1 did not show statisti-
cally significant elevation, but after 14 days, its con-
centration increased. As so, IL-6 can be used as a bio-
marker of early renal inflammatory damage to ESWL 
and IL-1 as a late one16.
The NGAL is a secretory protein (lipocalins) pres-
ent in the various cells (neutrophils, macrophages, epi-
thelial cells of kidneys, lung, etc.). Normal presence in 
the tissue is low, so notable elevation in serum and 
urine suggests diverse pathological conditions. Fahmy 
et al. evaluated 50 patients after ESWL for potential 
tubular damage by measuring the concentration of 
NGAL in urine before and on the first and fifth day 
after the procedure. They found mean NGAL concen-
trations were markedly heightened post ESWL and 
returned to baseline values within 2 weeks17.
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Cystatin C (CystC) is a protease inhibitor created 
by almost all cells in the human body at a steady rate, 
freely filtrated, not secreted or reabsorbed into the cir-
culation. Because of that, CystC serum level is inverse-
ly proportional to alterations in glomerular filtration 
rate. Estimation of GFR based on CystC levels is 
more precise than other biomarkers2. Salah et al. anal-
ysed the effect of ESWL on kidney function in 50 pa-
tients by measuring CystC before and after treatment 
and observed a fast rise in serum CystC concentration 
after the procedure18.
According to the data, there are still no consistent, 
reliable biomarkers in detecting acute kidney injury, 
and further studies involving urinary excretion of a 
broad variety of markers over a prolonged period of 
time are needed to predict and monitor potential long-
term side effects. The current guidelines for the Acute 
Dialysis Quality Initiative (ADQI) advise the inclu-
sion of only cystatin C and NGAL into the clinical 
practice19.
Long-term adverse effects
To date, the study that can fully and doubtlessly 
recognize the long-term effects of ESWL on kidneys 
and other bodily functions has not been conducted. 
Some studies have shown a greater risk of developing 
hypertension and diabetes mellitus.
A number of studies have proposed new-onset hy-
pertension as a potential long-term complication of 
ESWL at a follow-up period from 90 days to 19 years. 
Some studies have confirmed the correlation, and 
some have disproven it20-24.
Krambeck et al. performed a study in the form of a 
questionnaire at a mean follow-up of 19 years. Of 578 
patients who underwent ESWL treatment of kidney 
stones, 59% responded to the study. Results were 
matched up to a cohort of patients with kidney stones, 
who were treated conservatively, equalled for sex, age, 
and a year of onset, and they reported a significantly 
higher prevalence of hypertension in the ESWL group 
(odds ratio 1.47, 95% Cl 1.03-2.10)20.
A retrospective cohort study evaluated 4782 pa-
tients with nephrolithiasis who had no record of hy-
pertension at presentation and 400 (8.4%) patients 
were treated with ESWL. The study followed the pa-
tients for an average of 9 years and by the results, 
ESWL therapy was not associated with an increased 
risk of new-onset hypertension (adjusted hazard ratio 
1.03)21.
Among researches that suggest new-onset hyper-
tension, one prospective study by Janetschek et al. rec-
ognized age as a notable risk factor, with a rise in the 
internal resistive index in patients from 60 years of age 
and older22. Knapp et al. also recognized the increase in 
hypertension among older patients treated with 
ESWL23. Transient hypertension has been recorded in 
patients that developed subcapsular hematomas as a 
complication of ESWL24. Pathophysiological mecha-
nisms behind long-term effects of ESWL have not yet 
been determined, although Banner et al. reported me-
sangial cell proliferation in animal models with pigs 
one month after ESWL25.
As it is known that patients who suffer from uri-
nary tract stones have a greater chance of developing 
hypertension, the relation with ESWL has to be care-
fully analysed. As the data is inconsistent, further, long 
term, prospective studies should be conducted7,26.
Mayo Clinic did a retrospective 19-year follow-up 
study on 288 patients treated in 1985 with the HM3 
lithotripter, which indicated that patients who under-
went ESWL procedure had a greater chance to acquire 
diabetes mellitus than the control group (patients with 
kidney stones treated conservatively). This risk ap-
peared to directly correlate with the number of shocks 
administered and the treatment intensity20. A later 
study from the same centre pointed the disadvantages 
of the retrospective study, as the detection of diabetes 
was based on self-reporting questionnaires sent to all 
ESWL patients, with a concomitant Mayo Clinic 
medical record review to collect this data in the non-
ESWL patients. This may have introduced a differen-
tial detection bias, particularly since controls may have 
been diagnosed with diabetes at other institutions. 
This study in a large, community-based cohort of stone 
formers did not suggest that receiving ESWL using an 
HM3 lithotripter increased the risk of diabetes27.
As diabetes is a major life-altering possible compli-
cation, additional studies should be undertaken to 
evaluate the impact of ESWL on the pancreas and in-
sulin secretion.
Few studies have correlated the formation of cal-
cium phosphate stones (CaP) and brushite stones with 
a greater number of ESWL in the cohort28. It seems 
that the greater number of procedures turns patients 
with calcium oxalate stones into patients with CaP 
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stones, and as the number of the procedures grows, pa-
tients with CaP stones turn to patients with brushite 
stones, which are far harder to eliminate with ESWL. 
Changes in stone composition are linked with injuries 
of renal papilla, leading to functional alteration of col-
lecting ducts that result in the formation of crystalline 
deposits of apatite29.
As ESWL plays a major role in the treatment of 
kidney stones in children, the possible long-term ef-
fects on kidneys were investigated in several studies30. 
In all these studies, no long-term alterations of kidney 
function or the development of permanent renal scars 
were noticed30.
Optimization of the procedure  
to minorize the adverse effects of ESWL
It is well recognized that the possibility and the se-
verity of complications are directly connected to the 
number, firing rate, and energy level of SW4. That is 
why guidelines for safer ESWL treatment have been 
developed, but there is still no widely accepted proto-
col. The number of SW delivered during the treatment 
should range between 2000 and 40007. Ideally, the 
procedure should be stopped immediately as the stone 
fragmentation is achieved. Usually, the SW rate in 
ESWL for urologic use is from 60 to 120 SW per 
minute, but studies have shown that lower rates (30 to 
60 SW/min) are linked to both better stone fragmen-
tation and reduced tissue injury31,32. Stepwise increase 
of SW power − ramping − has several advantages. 
First, it is easier for patients to adapt to the discomfort 
of SW, it increases the chance of stone fragmentation, 
and shows a protective effect on kidney tissue33.
Conclusion
ESWL has proven to be a safe and effective meth-
od from its implementation 30 years ago and is still a 
valuable treatment option for kidney and upper ureter 
stones in both children and adults. Although numer-
ous side effects of SW have been described and stud-
ied, most of them are minor and can be minimized 
with adequate patient selection and procedure proto-
cols. Long-term effects of ESWL on kidney function 
and overall health need further investigation as cur-
rently available data is inconclusive.
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Sažetak
UTJECAJ IZVANTJELESNOG MRVLJENJA KAMENACA ŠOKNIM VALOVIMA NA BUBREG
K. Smolić i D. Markić
Izvantjelesno mrvljenje kamenaca (ESWL) novija je terapijska metoda u liječenju urolitijaze. Temelji se na uporabi 
 šok-valova koji se stvaraju u generatoru izvan tijela, fokusiraju i usmjeruju na kamenac u tijelu bolesnika. Metoda je izbora za 
liječenje bubrežnih kamenaca manjih od 20 mm te onih u proksimalnom dijelu mokraćovoda veličine do 10 mm. Komplika-
cije su relativno rijetke i najčešće klinički beznačajne. Šok valovi mogu reverzibilno oštetiti sve dijelove bubrežnog parenhima. 
Stupanj oštećenja ovisi o broju udaraca šok-valovima i energetskom nivou koji je isporučen određenom tkivu. Takve promje-
ne su najčešće asimptomatske. Mikrohematurija je prisutna praktički u svih bolesnika, a makrohematurija se javlja u oko 1/3 
bolesnika. Rijetka, ali ozbiljna komplikacija je ruptura bubrega koja zahtijeva operacijsko zbrinjavanje i ponekada nefrekto-
miju. Pojava perinefritičnog ili subkapsularnog hematoma je rijetka i obično prolazi na konzervativnu terapiju. Unatoč prije 
spomenutom negativnom utjecaju šok valova na bubrežni parenhim (prvenstveno na onaj u okolici kamenca) studije nisu 
pokazale da liječenje ovom metodom dovodi do značajnijeg oštećenja bubrežne funkcije niti u odrasloj, niti u pedijatrijskoj 
populaciji.
Ključne riječi: Izvantjelesno mrvljenje kamenaca šoknim valovima; Nefrolitijaza; Bubrežno oštećenje; Bubrežna funkcija
